Orexigen Therapeutics (OREX) Stock Price, News & Analysis

Company Overview

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Key Stats

• Today's Range: $0.22 to $0.32
• 50-Day Range: $0.22 to $0.22
• 52-Week Range: $0.17 to $3.81
• Volume: 3.74 million shs
• Average Volume: 1.16 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OREX Stock Analysis - Frequently Asked Questions

How were Orexigen Therapeutics' earnings last quarter?

Orexigen Therapeutics, Inc. (NASDAQ:OREX) released its earnings results on Monday, November, 13th. The biopharmaceutical company reported ($1.35) earnings per share for the quarter, topping the consensus estimate of ($2.13) by $0.78. The firm's revenue for the quarter was up 170.0% on a year-over-year basis.

What other stocks do shareholders of Orexigen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Orexigen Therapeutics investors own include Lexicon Pharmaceuticals (LXRX), Arena Pharmaceuticals (ARNA), MannKind (MNKD), Novavax (NVAX), Bristol Myers Squibb (BMY), Rexahn Pharmaceuticals (REXN) and ImmunoGen (IMGN).

Company Calendar

• Last Earnings: 11/13/2017
• Today: 8/02/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:OREX
• CIK: 1382911
• Web: www.orexigen.com
• Phone: 858-875-8600
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A